- Home
- SNDX vs DGII Comparison
SNDX vs DGII Comparison
Compare SNDX & DGII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- DGII
- Stock Information
- Founded
- SNDX 2005
- DGII 1985
- Country
- SNDX United States
- DGII United States
- Employees
- SNDX N/A
- DGII N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- DGII Computer peripheral equipment
- Sector
- SNDX Health Care
- DGII Technology
- Exchange
- SNDX Nasdaq
- DGII Nasdaq
- Market Cap
- SNDX 1.1B
- DGII 1.3B
- IPO Year
- SNDX 2016
- DGII N/A
- Fundamental
- Price
- SNDX $14.75
- DGII $36.30
- Analyst Decision
- SNDX Strong Buy
- DGII Buy
- Analyst Count
- SNDX 10
- DGII 4
- Target Price
- SNDX $38.40
- DGII $38.75
- AVG Volume (30 Days)
- SNDX 2.0M
- DGII 195.0K
- Earning Date
- SNDX 11-04-2025
- DGII 11-12-2025
- Dividend Yield
- SNDX N/A
- DGII N/A
- EPS Growth
- SNDX N/A
- DGII 147.46
- EPS
- SNDX N/A
- DGII 1.14
- Revenue
- SNDX $77,933,000.00
- DGII $420,935,000.00
- Revenue This Year
- SNDX $585.73
- DGII $2.46
- Revenue Next Year
- SNDX $94.17
- DGII $7.77
- P/E Ratio
- SNDX N/A
- DGII $32.01
- Revenue Growth
- SNDX 2126.66
- DGII N/A
- 52 Week Low
- SNDX $8.58
- DGII $22.39
- 52 Week High
- SNDX $22.50
- DGII $37.07
- Technical
- Relative Strength Index (RSI)
- SNDX 47.48
- DGII 61.38
- Support Level
- SNDX $15.71
- DGII $35.01
- Resistance Level
- SNDX $16.50
- DGII $36.94
- Average True Range (ATR)
- SNDX 0.81
- DGII 1.08
- MACD
- SNDX -0.36
- DGII 0.18
- Stochastic Oscillator
- SNDX 2.73
- DGII 81.87
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About DGII Digi International Inc.
Digi International Inc is a Minnesota corporation. The company provides business and mission-critical and Internet of Things (IoT) connectivity products and services. It has two segments: IoT Products and Services and IoT Solutions. The IoT Products and Services segment consists of distinct communications products and communication product development services. IoT Solutions segment offers wireless temperature and other environmental condition monitoring services as well as employee task management services. The company generates majority of its revenue from the IoT Products & Services segment. Geographically, the company generates majority of its revenue from its business in the United States and also has its presence in Europe, Middle East and Africa and Rest of the world.